Skip to main content
. 2021 Feb 5;16(6):1593–1603. doi: 10.1007/s11739-021-02655-6

Table 1.

Patient characteristics by corticosteroid treatment in the entire cohort and in the matched cohort

Unmatched (Entire) Cohort b Matched Cohort b
Characteristics a,c Corticosteroid Non-Corticosteroid stddiff Corticosteroid Non-Corticosteroid stddiff
n 615 846 385 385
Age, years
 18–50- 111 (18.1) 238 (28.1) 0.29 80 (20.8) 82 (21.3) 0.03
 50–65- 210 (34.1) 252 (29.8) 118 (30.6) 121 (31.4)
 65–80- 214 (34.8) 224 (26.5) 120 (31.2) 116 (30.1)
 ≥ 80 80 (13.0) 132 (15.6) 67 (17.4) 66 (17.1)
Gender
 Male 352 (57.2) 418 (49.4) − 0.16 201 (52.2) 200 (52.0) -0.01
 Female 263 (42.8) 428 (50.6) 184 (47.8) 185 (48.0)
Race
 Black/African American 389 (63.3) 532 (62.9) 0.08 228 (59.2) 239 (62.1) 0.07
 White/Caucasian 173 (28.1) 258 (30.5) 129 (33.5) 119 (30.9)
 Other 53 (8.6) 56 (6.6) 28 (7.3) 27 (7.0)
BMI, kg/m2
 < 30 252 (41.0) 360 (42.6) 0.03 156 (40.5) 156 (40.5) 0.00
 ≥ 30 363 (59.0) 486 (57.4) 229 (59.5) 229 (59.5)
Comorbidity
 Myocardial Infarction 85 (13.8) 71 (8.4) 0.17 49 (12.7) 39 (10.1) 0.08
 Diabetes Mellitus 198 (32.2) 236 (27.9) 0.09 123 (31.9) 115 (29.9) 0.04
 Hypertension 352 (57.2) 399 (47.2) 0.20 205 (53.2) 200 (52.0) 0.03
 Charlson weighted score (disease only)

3.2 ± 2.4

3.0 (1.0, 5.0)

2.7 ± 2.4

2.0 (1.0, 4.0)

0.20

3.3 ± 2.5

3.0 (1.0, 5.0)

3.1 ± 2.4

3.0 (1.0, 4.0)

0.06
 Number of ED visits prior to 6 months

0.4 ± 1.0

0.0 (0.0, 1.0)

0.4 ± 1.0

0.0 (0.0, 0.0)

0.03

0.5 ± 1.0

0.0 (0.0, 1.0)

0.4 ± 1.0

0.0 (0.0, 0.0)

0.06
Initial Vital Signs
 Systolic blood pressure, mmHg

131.2 ± 20.7

129.0 (118.0, 142.0)

131.4 ± 19.7

130.0 (118.0, 143.0))

-0.02

131.5 ± 20.4

130.0 (120.0, 140.0)

132.4 ± 18.9

132.0 (120.0, 143.0)

− 0.06
 Diastolic blood pressure, mmHg

72.4 ± 11.6

72.0 (64.0, 80.0)

73.6 ± 12.3

73.0 (66.0, 82.0)

-0.09

72.8 ± 11.7

73.0 (64.0, 81.0)

73.0 ± 11.7

72.0 (65.0, 80.0)

0.00
 Pulse, beats per minute

92.0 ± 15.7

92.0 (81.0, 102.0)

89.8 ± 14.7

90.0 (79.0, 100.0)

0.12

90.4 ± 15.7

90.0 (79.0, 100.0)

91.2 ± 13.8

91.0 (81.0, 101.0)

-0.08
 Temperature, ℉

100.4 ± 1.6

100.3 (99.0, 101.8)

100.3 ± 1.6

100.2 (99.0, 101.5)

0.05

100.3 ± 1.7

100.2 (98.9, 101.7)

100.3 ± 1.7

100.2 (99.0, 101.7)

0.00
Respiratory rate, breaths per minute
 < 24 360 (58.5) 613 (72.5) 0.30 248 (64.4) 252 (65.5) 0.02
  ≥ 24 255 (41.5) 233 (27.5) 137 (35.6) 133 (34.5)
Blood oxygen saturation, %
  ≤ 88 266 (43.2) 167 (19.7) 0.56 121 (31.4) 118 (30.6) 0.07
 88 + to 94- 207 (33.7) 316 (37.4) 148 (38.4) 157 (40.8)
  ≥ 94 142 (23.1) 363 (42.9) 116 (30.1) 110 (28.6)
Medications
 Hydroxychloroquine 573 (93.2) 500 (59.1) 0.87 343 (89.1) 339 (88.1) 0.03
 Azithromycin 589 (95.8) 623 (73.6) 0.65 360 (93.5) 358 (93.0) 0.02
 Vitamin C 276 (44.9) 131 (15.5) 0.68 121 (31.4) 114 (29.6) 0.04
 Zinc 248 (40.3) 124 (14.7) 0.60 111 (28.8) 102 (26.5) 0.05
 ACE inhibitors/ARB/sartanics 127 (20.6) 174 (20.6) 0.00 85 (22.1) 87 (22.6) − 0.01
Initial laboratory tests
White blood cell count × 109/L
 < 4 65 (10.6) 118 (13.9) 0.16 51 (13.2) 46 (11.9) 0.03
 4 to 10 443 (72.0) 625 (73.9) 276 (71.7) 281 (73.0)
 > 10 107 (17.4) 103 (12.2) 58 (15.1) 58 (15.1)
Lymphocyte count × 109/L
  < 0.8 212 (34.5) 257 (30.4) 0.09 126 (32.7) 128 (33.2) − 0.01
  ≥ 0.8 403 (65.5) 589 (69.6) 259 (67.3) 257 (66.8)
Hemoglobin, g/dL
 ≤ 11 92(15.0) 146 (17.3) − 0.06 76 (19.7) 68 (17.7) 0.05
 > 11 523 (85.0) 700 (82.7) 309 (80.3) 317 (82.3)
ALT, U/L
  ≤ 40 406 (66.0) 575 (68.0) − 0.04 255 (66.2) 260 (67.5) − 0.03
 > 40 209 (34.0) 271 (32.0) 130 (33.8) 125 (32.5)
Creatinine, mg/dL
  ≤ 1.33 350 (56.9) 553 (65.4) − 0.17 236 (61.3) 235 (61.0) 0.01
 > 1.33 265 (43.1) 293 (34.6) 149 (38.7) 150 (39.0)
Lactate dehydrogenase, U/L
 ≤ 245 51 (8.3) 155 (18.3) − 0.30 46 (11.9) 38 (9.9) 0.07
  > 245 564 (91.7) 691 (81.7) 339 (88.1) 347 (90.1)
D-dimer, ng/mL FEU
 ≤ 500 93 (15.1) 189 (22.3) 0.24 69 (17.9) 76 (19.7) 0.06
 500–1000 179 (29.1) 279 (33.0) 122 (31.7) 116 (30.1)
 > 1,000 343 (55.8) 378 (44.7) 194 (50.4) 193 (50.1)
Procalcitonin, ng/mL
 < 0.1 164 (26.7) 372 (44.0) 0.39 128 (33.3) 123 (31.9) 0.06
 0.1–0.25 181 (29.4) 231 (27.3) 114 (29.6) 110 (28.6)
 0.25–0.5 108 (17.6) 91 (10.8) 52 (13.5) 60 (15.6)
 > 0.5 162 (26.3) 152 (18.0) 91 (23.6) 92 (23.9)
C-reactive protein, mg/L
 < 50 100 (16.3) 241 (28.5) 0.42 78 (20.3) 80 (20.8) 0.03
 50–100 138 (22.4) 251 (29.7) 101 (26.2) 102 (26.5)
 > 100 377 (61.3) 354 (41.8) 206 (53.5) 203 (52.7)
Lactic acid, mmol/L
 < 2 460 (74.8) 674 (79.7) − 0.12 301 (78.2) 298 (77.4) 0.02
  ≥ 2 155 (25.2) 172 (20.3) 84 (21.8) 87 (22.6)

BMI body mass index, ALT alanine aminotransferase, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, stddif standardized difference

aFor continuous variables, means ± standard deviations and medians (interquartile ranges, IQRs) were presented. For categorical variables, frequencies and percentages within parentheses were presented

bThe standardized difference of clinical characteristics was less than 10% to indicate the balance on corticosteroid and non-corticosteroid groups

cMissing data on BMI, vital signs, and laboratory tests were imputed for the entire cohort analysis and the propensity score matching analysis. Descriptive results from one of the imputed datasets were shown